Gilead Sciences, Inc. (NASDAQ:GILD) delivered strong fiscal Q2 2026 results, with total revenue rising 10% year over year to ...
It's a twice-a-year injection that is remarkably effective in preventing an HIV infection. Distribution is starting. But questions are being raised about getting it to the areas that need it most.
This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. A new sequential immunization strategy shows strong promise for an HIV vaccine, a ...
AllAfrica on MSN
What Are Broadly Neutralising Antibodies and What Do They Mean for the Fight Against HIV?
HIV is known for its ability to outsmart our immune system's normal defences. A small number of people living with the virus are however able to generate unusually effective immune responses. In this ...
Gilead's twice-yearly shot reduced HIV infections by 96% in a second large study, the company said. The data sets the stage for likely FDA approval of lenacapavir for HIV prevention. Shares rose 3% in ...
For years, Philip Goulder has been obsessed with a particularly captivating idea: In the hunt for an HIV cure, could children hold the answers? Starting in the mid-2010s, the University of Oxford ...
Tuberculosis (TB) is responsible for about a quarter of all AIDS deaths. In 2024, it was also the leading cause of death among people with HIV. This is despite TB being a preventable and curable ...
The Wichita Beacon on MSN
‘We are living in reverse.’ Fragile HIV funding puts another strain on Kansas City’s safety net
HIV health providers have already absorbed some cuts and fear more. They worry that gains made toward eliminating the virus are in jeopardy. The post ‘We are living in reverse.’ Fragile HIV funding ...
International health organisations and experts say antiretroviral therapy and medication helps people living with HIV to live ...
This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. NAKURU, KENYA - 2026/03/26: A healthcare worker fills a syringe with a dose of lenacapavir, ...
In the early decades of the global response to HIV/AIDS, the focus was on saving lives. And rightly so: without antiretroviral treatment (ART), people lived less than a year, on average, from the time ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results